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a b s t r a c t
Alzheimer disease (AD) is a neuronal dementia for which no treatment has been consolidated yet. Major
pathologic hallmark of AD is the aggregated extracellular amyloid-b plaques in the brains of disease suf-
ferers. Ab-peptide is a major component of amyloid plaques and is produced from amyloid precursor pro-
tein (APP) via the proteolysis action. An aspartyl protease known as b-site amyloid precursor protein
cleaving enzyme (BACE-1) is responsible for this proteolytic action. Distinctive role of BACE-1 in AD path-
ogenesis has made it a validated target to develop anti-Alzheimer agents. Our structure-based virtual
screening method led to the synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydro-
pyridine BACE-1 inhibitors (6a–6p; in vitro hits). Molecular docking and DFT-based ab initio studies using
B3LYP functional in association with triple-f basis set (TZV) proposed binding mode and binding energies
of ligands in the active site of the receptor. In vitro BACE-1 inhibitory activities were determined by enzy-
matic fluorescence resonance energy transfer (FRET) assay. Most of the synthesized dihydropyridine scaf-
folds were active against BACE-1 while 6d, 6k, 6n and 6a were found to be the most potent molecules
with IC50 values of 4.21, 4.27, 4.66 and 6.78 lM, respectively. Superior BACE-1 inhibitory activities were
observed for dihydropyridine derivatives containing fused/nonfused thiazole containing groups, possibly
attributing to the additional interactions with S2–S3 subpocket residues. Relatively reliable correlation
between calculated binding energies and experimental BACE-1 inhibitory activities was achieved
(R2 = 0.51). Moreover, compounds 6d, 6k, 6n and 6a exhibited relatively no calcium channel blocking
activity with regard to nifedipine suggesting them as appropriate candidates for further modification(s)
to BACE-1 inhibitory scaffolds.
Ó 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Alzheimer disease (AD) is a neurodegenerative disorder clini-
cally recognized by progressive decline in memory and cognition.1
AD accounts for most cases of dementia in the elderly popula-
tion.2,3 Histological examination of the brains of affected individu-
als has revealed the existence of significant synaptic loss.4 The
main neuropathological characteristics of AD are the presence of
extracellular amyloid plaques and intracellular Neurofibrillary tan-
gles (NFT) in the brain. The amyloid plaques result from the depo-
sition of aggregated amyloid beta (Ab) peptides. Ab peptides
(mainly as Ab40 and Ab42) are the product of two consecutive pro-
teolytic cleavages on a large trans-membrane protein; amyloid
precursor protein (APP).
By 1999, various independent researchers discovered BACE-1 as
the aspartyl protease b-site APP-cleaving enzyme. BACE-1 initiates
the amyloid cascade by cleavage of APP.5,6 Subsequent cleavage of
the C-terminus of APP by c-secretase results in the formation of
Ab40 and Ab42. In the nonamyloidogenic pathway, a-secretase
cleaves APP leading to the generation of neuroprotective peptide
sAPPa.7
Inhibition of b and c-secretase enzymes by small molecule
blockers is a promising approach to find therapeutic agents for
AD. In this regard, inhibition of b-secretase is very importance
since several studies have shown that inhibition of c-secretase
may have some mechanism-based adverse effects.8,9 The strategy
of BACE-1 blockade for AD-therapy has been further supported
by the observation of normal phenotype in BACE-1 knockout
mice.10
Many research groups have focused on the development of
BACE-1 inhibitors.11,12 BACE-1 inhibitors were primarily designed
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